Welcome to our dedicated page for Annovis Bio news (Ticker: ANVS), a resource for investors and traders seeking the latest updates and insights on Annovis Bio stock.
Annovis Bio, Inc. (NYSE: ANVS) generates a steady flow of news as a late-stage clinical drug platform company focused on neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). This news page aggregates announcements that reflect the company’s progress in clinical development, regulatory interactions, scientific presentations, and corporate activity.
Readers can follow updates on buntanetap, Annovis’ lead drug candidate, across multiple indications. News items include milestones from the pivotal Phase 3 trial in early Alzheimer’s disease, such as activation of clinical sites, enrollment status, and timing of key readouts. In Parkinson’s disease, press releases cover Phase 3 data analyses, biomarker findings related to amyloid co‑pathology and tau measures, and the design and objectives of the Open-Label Extension study that evaluates long-term safety and efficacy in diverse patient cohorts, including those receiving deep brain stimulation.
Company news also highlights regulatory developments, including scheduled FDA meetings to discuss the pathway for Parkinson’s disease dementia and confirmation of alignment on Phase 3 Alzheimer’s study design and endpoints. Scientific communications feature presentations at major conferences focused on Parkinson’s disease and Alzheimer’s clinical trials, where Annovis shares biomarker data, cross-study comparisons, and analyses of cognitive outcomes in patients with defined biomarker profiles.
In addition to clinical and scientific updates, this feed includes corporate events such as earnings releases, capital raises through registered direct offerings, leadership changes, and NYSE listing compliance disclosures. Investors, clinicians, and other stakeholders can use this page to track how Annovis communicates its trial progress, financial condition, and strategic priorities over time. For those following ANVS stock or the development of buntanetap in Alzheimer’s and Parkinson’s disease, this news stream provides a consolidated view of the company’s publicly reported milestones.
Annovis Bio, a clinical-stage company targeting neurodegenerative diseases, reported its Q2 2022 financial results. The FDA approved the Phase 3 clinical trial design for its drug, buntanetap, in early Parkinson's patients. The company also submitted an international patent for treating neurological injuries from infections and announced a collaboration with the National Institute on Aging to develop biomarkers. Financially, it holds $36 million in cash, with Q2 expenses totaling $8.7 million in net losses compared to $2.5 million a year prior.
Annovis Bio, Inc. (NYSE: ANVS) announced that CEO Maria Maccecchini will participate in a panel on the Systems Biology of Alzheimer's Disease at the Alzheimer's Association International Conference on August 4, 2022. The panel aims to discuss advanced therapeutic approaches for Alzheimer's and features notable experts including Jeffrey Cummings and Krista Lanctôt. The company’s drug, Buntanetap, has shown promise in improving cognition in Alzheimer's patients and motor function in Parkinson's patients during Phase 2 clinical trials. For more info, visit www.annovisbio.com.
Annovis Bio, Inc. (NYSE: ANVS) announced that its Founder, President, and CEO, Maria Maccecchini, Ph.D., will participate in the Systems Biology of Alzheimer's Disease Panel at the Alzheimer's Association International Conference on August 4, 2022. The panel, moderated by Jeffrey Cummings, MD, and Krista Lanctôt, Ph.D., will discuss innovative therapeutic approaches for Alzheimer's disease. Buntanetap, Annovis's lead compound, has shown promise in clinical trials, improving cognition in Alzheimer's and motor function in Parkinson's patients.
Annovis Bio, Inc. (NYSE: ANVS) announced that the FDA has approved its Phase 3 clinical study of buntanetap for early Parkinson's disease. Following a successful Type B meeting earlier this year, the FDA accepted the final protocol and clinical development plan, allowing longer duration studies. The study will involve 100 sites in the US and EU, with expected recruitment later this summer. Previous Phase 2 trials indicated statistically significant improvements in motor function for PD and cognitive function for AD patients. This progress positions Annovis favorably in the neurodegenerative treatment landscape.
Annovis Bio has submitted an international patent application for Buntanetap, its lead compound, to treat neurological injuries caused by infections. This patent aims to expand its existing intellectual property portfolio, which already covers various neurodegenerative diseases like Alzheimer's and Parkinson's. If granted, the patent could protect the company’s innovations until 2042. Data indicates Buntanetap decreases neurotoxic protein levels and shows promise in clinical trials, enhancing cognitive and motor functions in patients.
Lantern Pharma (NASDAQ: LTRN) announced Dr. Maria L. Maccecchini as a nominee for its Board of Directors during the Annual Meeting on June 8, 2022. Dr. Maccecchini, a seasoned biopharmaceutical executive, brings decades of experience, particularly in neurodegenerative diseases. Concurrently, Leslie W. Kreis, Jr. will not seek reelection. Lantern's President, Panna Sharma, emphasized Dr. Maccecchini's potential contributions to ongoing clinical trials. Lantern is focused on utilizing its RADR® platform to enhance oncology drug development.
Annovis Bio, Inc. (NYSE American: ANVS), a clinical-stage company focused on neurodegenerative diseases, will have CEO Maria L. Maccecchini present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available on demand for attendees. Annovis is developing treatments targeting Alzheimer's and Parkinson's diseases, with ongoing Phase 2 studies assessing their drug's efficacy in improving memory loss and brain function. For more details, visit www.annovisbio.com.
On March 11, 2021, Annovis Bio, ANVS, announced that Dr. Maria Maccecchini, its Founder and CEO, will attend the Q1 Virtual Investor Summit from March 23-25, 2021. Dr. Maccecchini's presentation is scheduled for March 24 at 11:30 AM ET. The summit aims to connect smallcap and microcap companies with investors, featuring 100 companies and over 300 participants.
For registration details, visit www.investorsummitgroup.com. Annovis focuses on developing treatments for neurodegenerative diseases like Alzheimer's and Parkinson's.
On February 16, 2021, Annovis Bio (NYSE: ANVS), a clinical-stage company focused on treatments for neurodegenerative diseases, announced that Dr. Maria Maccecchini will present at the BIO CEO & Digital Conference from February 16-18. The presentation will be available on demand for registered attendees. Annovis Bio aims to address Alzheimer's disease, Parkinson's disease, and Alzheimer’s in Down Syndrome by developing a unique drug that targets multiple neurotoxic proteins, improving nerve cell function. The company is conducting two Phase 2a trials on patients with AD and PD.
On December 17, 2020, Annovis Bio (NYSE American: ANVS) announced that CEO Maria Maccecchini, Ph.D., will be featured in an interview on The RedChip Money Report. The program reaches 100 million homes across Europe and airs on Sundays at 6 p.m. local time on Bloomberg International. In the interview, Maccecchini discusses Annovis' innovative approach to treating Alzheimer’s disease (AD) and other neurodegenerative diseases, the ongoing clinical trials, and anticipated milestones. Annovis is developing a drug aimed at improving nerve cell function affected by neurotoxic proteins.